HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $11 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Candel Therapeutics (NASDAQ:CADL) and maintained an $11 price target for the company's stock.
November 13, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Candel Therapeutics' stock rating has been reaffirmed as Buy by HC Wainwright & Co. with a price target of $11, indicating a positive outlook on the stock.
The reiteration of a Buy rating and the maintenance of a price target often signal an analyst's continued confidence in a company's stock performance. This can positively influence investor sentiment and potentially lead to a short-term increase in the stock price, especially if the target suggests significant upside from the current trading level.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100